ஜர்னல் ஆஃப் லிவர்: நோய் மற்றும் மாற்று அறுவை சிகிச்சை

Sorafenib and Mammalian Target of Rapamycin Inhibitors after Liver Transplantation: A Single-Center Experience and Review of the Literature

Damiano Patrono, Stefano Mirabella, Elisabetta Magra, Marco Palisi, Renato Romagnoli and Mauro Salizzoni

Sorafenib and Mammalian Target of Rapamycin Inhibitors after Liver Transplantation: A
Single-Center Experience and Review of the Literature

Hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) is observed in 10-15% of the patients and generally has a dismal prognosis. Little is known about the safety and efficacy of a therapeutic regimen including sorafenib and mammalian target of rapamycin inhibitors (mTORi) in this setting. The medical charts of the recipients of a LT presenting HCC recurrence and treated with sorafenib either alone
or in combination with mTORi were retrospectively reviewed.